Telomir Pharmaceuticals, Inc. 8-K

What Happened
Telomir Pharmaceuticals, Inc. announced on March 31, 2026 that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate Telomir‑1 (Telomir‑Zn) to treat advanced and metastatic triple‑negative breast cancer (TNBC). The IND package includes completed IND‑enabling pharmacology, toxicology and manufacturing studies. Subject to FDA clearance, the company plans a Phase 1/2 oral monotherapy trial: a standard 3+3 dose‑escalation for Phase 1 to assess safety, tolerability and dose‑limiting toxicities, with a Phase 2 Simon two‑stage design using objective response rate (ORR) as the primary endpoint.

Key Details

• IND submission date: March 31, 2026; IND includes pharmacology, toxicology and manufacturing data.
• Planned clinical design: Phase 1 — standard 3+3 dose escalation; Phase 2 — Simon two‑stage design; primary endpoint ORR.
• Preclinical data: Telomir‑Zn showed reduced tumor growth and metastatic dissemination in TNBC models and induced iron‑dependent tumor cell death across several human TNBC cell lines.
• Safety package: IND‑enabling GLP safety studies reported no treatment‑related adverse events or dose‑limiting toxicities. Company is also developing biomarker strategies and has submitted manuscripts and plans AACR 2026 presentations.

Why It Matters
Filing an IND is a key regulatory milestone that, if cleared by the FDA, permits Telomir to begin human testing of Telomir‑1 — a first‑in‑class, metal‑modulating small molecule designed to alter intracellular iron and zinc and inhibit iron‑dependent epigenetic enzymes. The company’s GLP safety results and reported preclinical efficacy are relevant to early clinical risk assessment, and planned biomarker work and conference presentations (AACR 2026) are near‑term developmental updates to watch.